MARKET

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.2481
-0.0019
-0.76%
After Hours: 0.2100 -0.0381 -15.36% 18:47 11/15 EST
OPEN
0.2500
PREV CLOSE
0.2500
HIGH
0.2579
LOW
0.2400
VOLUME
610.32K
TURNOVER
--
52 WEEK HIGH
0.7085
52 WEEK LOW
0.1900
MARKET CAP
40.86M
P/E (TTM)
-1.2902
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ATNM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ATNM News

  • Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference
  • PR Newswire.11/07 21:05
  • Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019
  • PR Newswire.11/06 14:15
  • Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019
  • PR Newswire.11/06 14:00
  • Mid-Afternoon Market Update: Crude Oil Down Over 1%; Liberty Property Trust Shares Spike Higher
  • Benzinga.10/28 19:09

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About ATNM

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
More

Webull offers Actinium Pharmaceuticals Inc (ATNM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.